| 2019 | Nov | Received Ministerial Citation by Ministry of Health and Welfare, South Korea |
| Sep | Established Scientific Advisory Board and held 1st Exosome in Medicine Symposium | |
| Aug | Selected for Future Medical Business One-Stop Support Initiative by Korea Health Industry Development Institute | |
| Mar | Received R21 NIH grant for exosome-based research Relocated corporate headquarter to Daedeok Techno Valley, Daejeon, South Korea |
|
| Jan | Established ILIAS Therapeutics, Inc. in New York, U.S.A. |
| 2018 | May | Series A funding (~$17M) |
| 2017 | Nov | Opened Pangyo research lab in Institute Pasteur Korea |
| Oct | Opened Seoul office in Seoul Bio Hub |
| 2016 | Sep | 2nd angel funding |
| May | Designated as K-Healthcare Start-Up by Korean Health Industry Development Institute | |
| Feb | 1st angel funding |
| 2015 | Nov | Incorporated in Daejeon, South Korea and certified as Venture Company with research facilities |